Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 8/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392728 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL4338960 | 0.80 | TBXAS1 (0.49) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL28843269 | 0.78 | TBXAS1 (0.47) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| Bromide SCHEMBL28286964 | 0.78 | TBXAS1 (0.47) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL26660791 | 0.78 | TBXAS1 (0.51) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL28328253 | 0.78 | TBXAS1 (0.50) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| Iodide SCHEMBL27677678 | 0.78 | TBXAS1 (0.47) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL4342783 | 0.77 | TBXAS1 (0.54) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL22827209 | 0.75 | TBXAS1 (0.45) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL13919194 | 0.75 | TBXAS1 (0.45) | TBXAS1CYP19A1CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894052-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-19 | — | — | US | disclosed |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | Bristl-Myers Squibb Company (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | APLNR, GPBAR1, AGTR1 | TBXAS1 193/4885CYP19A1 1216/4885CYP17A1 848/4885 |
| US-10894052-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | TBXAS1 1310/4885CYP19A1 2459/4885CYP17A1 3522/4885 |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | TBXAS1 1310/4885CYP19A1 2459/4885CYP17A1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.